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ABSTRACT Human immunodeficiency virus type 1
(HIV-1) infections of humans have a natural history charac-
terized by a variable but usually slow pogion to an
immunodeficient state. We have described a molecular model
of HIV-1 proviral latency in certain cell lines, characterized by
extremely low or undetectable levels of unspliced genomic
HIV-1-specific RNA but significant levels of multiply spliced
HIV-1-specific RNA. We have utllized a quantitative reverse
transcriptase-initiated polymerase chain reaction to measure
the levels of various HIV-1 RNA species in peripheral blood
mononuclear cells. The median level of multiply spliced HIV-1
RNA was dramatically higher than the median level of un-
spliced viral RNA in asymptomatic individuals. In addition,
HIV-1 RNA patterns characterized by at least a 10-fold excess
of multiply spliced to unspliced viral RNA were significantly
more common in asymptomatic individuals than in patients
with the acquired immunodeficlency ndrome. We suggest
that asymptomatic clinical HIV-1 infection is characterized by
a preponderance of HIV-1-infected peripheral blood cells
blocked at an early stage of HIV-1 infection. This viral expres-
sion pattern, which we have called blocked early-stage latency,
may constitute a reservoir of latently infected cells in certain
HIV-1-infected persons.
Infection of people by human immunodeficiency virus type 1
(HIV-1) is usually marked by three general stages of disease
progression (1-6). After initial infection, the individual un-
dergoes a state of rapid viral replication and seroconversion
to a variety of HIV-1 antigens (1-6). Within a few weeks or
months, this initial viremia subsides, leading to the second
phase of clinical infection characterized by a variable, but
usually prolonged, period of relatively quiescent infection,
with low viremia, but a slow depletion of CD4-positive T
lymphocytes. During this virtually latent clinical stage of
HIV-1 infection, the replicative state ofthe virus is unknown.
As the host's immune system gradually deteriorates, this
clinically latent state of infection evolves into a third stage of
increasing viral replication, with increasing numbers of pe-
ripheral blood cells harboring the HIV-1 genome and exten-
sive CD4-positive lymphocyte depletion (4-6).
The U1 monocytoid and the ACH-2 T-lymphocytic cell
lines harbor HIV-1 in a latent form, in that the cells, although
infected, constitutively produce very small quantities of
HIV-1 (7, 8). Virus production can be induced in these cells
by treatment with a variety of agents (7-10). The HIV-1-
specific RNAs may be separated into three classes, according
to their sizes. The multiply spliced (2 kilobases) species
encode the regulatory proteins Tat, Rev, and Nef. The singly
spliced (4.3 kilobases) species encode at least the envelope
proteins, and the unspliced (9.2 kilobases) HIV-1 RNA
species function as both the viral genomic RNA and as
mRNA for the Gag-Pol and Gag proteins (11-13). We have
shown (11), and it has been confirmed (12), that latently
infected cell lines, in the unstimulated state, express viral
RNA that consists of singly and multiply spliced HIV-1
mRNA species with little or no unspliced HIV-1 RNA.
Stimulation causes a dramatic upregulation in the rate of viral
RNA transcription and a subsequent switch to predominant
synthesis of the unspliced form of HIV-1 RNA (11, 12). This
switch from predominantly spliced HIV-1 RNAs to increas-
ing levels of unspliced HIV-1 RNA also occurs during an
acute productive infection of T lymphocytes and monocyte/
macrophages and has been described as a switch from the
early to the late stage of retroviral infection (13). Thus, the
unstimulated latently infected lines behave like early-stage
infected cells but are blocked from progression to the late
stage unless externally stimulated. We have proposed a
molecular model of proviral latency in these cells lines, in
which the low levels of viral production are a consequence of
their inability to switch to the late stage of infection (11). This
blocked early-stage latency may be due to low levels of
transcription and, thus, a low level of the viral-encoded
protein Rev, which is required for the accumulation of
unspliced HIV-1 RNA (14).
Amounts of viral RNA per cell are difficult to measure
because the number of infected cells and the distribution of
viral RNA content in different cells must be known. The
pattern of viral RNA is easier to ascertain and it provides
average sampling of viral RNA but will be dominated by cells
with a relatively high content of viral RNA. We have spec-
ulated that clinical HIV-1 latency during a human infection
might involve a predominance of blocked early-stage cells
that harbor a latent infection, like that of the latently infected
cell lines (11). In this paper, we report a test ofthis possibility,
utilizing a quantitative HIV-1 reverse transcriptase (RT)-
initiated polymerase chain reaction (PCR) to separately de-
termine the levels of unspliced and multiply spliced HIV-1
RNA species.
METHODS
Patients and RNA Samples. Heparinized blood specimens
were obtained from 52 HIV-1-seropositive adults, all un-
treated for at least 1 month with anti-retroviral agents. Blood
specimens were also drawn from 8 HIV-1-seronegative indi-
viduals. All specimens were evaluated in a blinded fashion.
The HIV-1-infected individuals were classified by their clin-
ical state of disease, using the modified CDC HIV classifi-
cation scheme (15). Twenty individuals were classified as
asymptomatic (stage 2), 13 had solely persistent generalized
Abbreviations: HIV-1, human immunodeficiency virus type 1; RT,
reverse transcriptase; PBMC, peripheral blood mononuclear cell.
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lymphadenopathy (stage 3), and 19 had the acquired immu-
nodeficiency syndrome (AIDS) (stages 4 A-D). Peripheral
blood mononuclear cells (PBMCs) were isolated by Ficoll/
Hypaque gradient centrifugation. Total cellular RNA was
harvested from these unstimulated PBMCs by using a one-
step acid guanidinium method, as described (16).
Quantitative RT-PCR. A RT-PCR technique, as described
(17), was modified to obtain precise quantitation ofthe copies
of selected HIV-1 RNA species in each sample (18). Quan-
tities of total cellular RNA were adjusted to be within the
linear amplification ranges of the standard curves (see be-
low). The 3' primers were annealed and extended as de-
scribed (17). A tube without RT was used as a negative
control to test for DNA contamination in all experiments.
The upstream primers were radioactively labeled using
['y-32P]ATP. Thus, a hybridization step using a labeled probe
was not necessary (17, 18). Samples were resolved on a
nondenaturing 8% polyacrylamide gel. Specific bands were
excised and radioactivity was measured using liquid scintil-
lation.
A major modification of this protocol, which allowed
precise quantitation of each HIV-1 RNA species in the
samples, was the use of standard curves of in vitro tran-
scribed RNAs (18). The concentrations of the in vitro tran-
scribed standard RNAs were measured spectrophotometri-
cally and the copy number of transcripts present in 1 Al of
solution was calculated, using the molecular weight of the
transcript and Avogadro's number. Serial 1:2 dilutions of the
RNA standards were made. Precise standard curves could,
therefore, be generated in parallel. In the linear amplification
range of these curves, the copies of in vitro-transcribed
RNAs were plotted against the cpm of radioactivity of the
amplified fragments. By using these dilution curves of in
vitro-transcribed RNA, the copy numbers of unspliced and
multiply spliced HIV-1 RNA, per microgram of total cellular
RNA in a sample, could be calculated by extrapolation to
these standard curves. Primers selected for this PCR proce-
dure were in extremely conserved regions of the HIV-1
genome to facilitate detection of the various strains of HIV-1
found in clinical specimens (18, 19). The primers for multiply
spliced RNA were located in the first and second exons of tat
and rev and the primers for unspliced RNA flanked the major
splice donor site (18).
Statistical Analyses. The Wilcoxon signed rank test was
utilized to compare differences in the median levels of viral
RNA species within each stage of disease. This nonparamet-
ric test was used as the normality of the distributions could
not be assumed. Fischer's exact test was used to compare
differences in viral RNA expression patterns between groups
of patients.
RESULTS
By utilizing serial dilution curves, productively HIV-1-
infected H9 lymphocytic cells gave approximately equal
amounts of multiply spliced and unspliced HIV-1 RNA (Fig.
1A and B), as expected for most productive infections (11).
Samples were quantitated by extrapolation to a standard
curve, by using in vitro-transcribed RNA from genomic
HIV-1 DNA and multiply spliced HIV-1 cDNA fragments
(Fig. 1 C and D). Three representative patient samples are
presented in Fig. 1E. Lanes 1 and 2 show a productive pattern
with approximately equal amounts of these two types of
HIV-1 RNA. Lanes 3 and 4 show a 20-fold excess of multiply
spliced HIV-1 RNA. Lanes 5 and 6 show an extreme case,
with multiply spliced but no detectable unspliced HIV-1
RNA. Lanes 7 and 8 show that an uninfected individual's
cells are negative in both assays. Lanes 9 and 10 show that
uninduced U1 cells gave the expected pattern of analysis,
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FIG. 1. Quantitation of unspliced and multiply spliced HIV-1-
specific RNA species by a RT-PCR. (A and B) Autoradiographs of
serial 1:2 dilutions of total cellular RNA isolated from productively
HIV-1-infected H9 cells, after RT-PCR. (A) Unspliced HIV-1 RNA.
(B) Multiply spliced HIV-1 RNA. (C and D) Autoradiographs of
serial 1:2 dilutions of in vitro transcribed HIV-1 RNA standards, after
RT-PCR. (C) Unspliced HIV-1 RNA. (D) Multiply spliced HIV-1
RNA. (E) Representative autoradiographs of total cellular RNA,
harvested from PBMCs and subjected to RT-PCR (M, multiply
spliced HIV-1 RNA; U, unspliced HIV-1 RNA). Lanes: 1 and 2,
productive pattern (unspliced to multiply spliced ratio, 1:1); 3 and 4,
blocked early-stage latent pattern (unspliced to multiply spliced
ratio, 1:20); 5 and 6, blocked early-stage latent pattern, with no
unspliced HIV-1 RNA detected; 7 and 8, HIV-1-seronegative con-
trol; 9 and 10, U1 cells (unstimulated); 11, DNA marker lane
(pBR322, Msp I digest). Arrows point to specific amplified PCR
products. Molecular sizes in base pairs are shown.
with significantly more multiply spliced than unspliced HIV-1
RNA (11).
For all 52 HIV-1-infected individuals, classified by the
modified CDC HIV classification scheme (15), HIV-1 RNA
was detectable in their PBMCs, by using the quantitative
HIV-1 RT-PCR (Table 1), in agreement with a recent report
(20). None of the HIV-1-seronegative controls were positive
for any HIV-1 RNA species. Although the levels of HIV-1
RNAs detected varied extensively, the median levels of
HIV-1-specific RNA species in certain disease stages were
informative (Table 2). The most obvious trend was that the
median ratio of multiply spliced to unspliced HIV-1 RNA in
the stage 2 (asymptomatic) individuals was 85 and the median
ratio in the stage 3 (persistent generalized lymphadenopathy)
and stage 4 (AIDS) individuals was 3 to 5 (Table 2). The
difference between the median levels of unspliced and mul-
tiply spliced HIV-1 RNA, in stage 2 individuals, was highly
significant (P < 0.001, Wilcoxon signed rank test). The
differences between median levels of unspliced and multiply
spliced viral RNA were not significant in stage 3 or stage 4
patients. The relative excess of multiply spliced HIV-1 RNA
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Table 1. Levels of HIV-i-specific RNA species ir
HIV-i-infected individuals by a quantitative RT-PC
HIV-1-specific RNA
Stage Patient
2 (n = 20) 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
3 (n = 13) 21
22
23
24
25
26
27
28
29
30
31
32
33
4 (n = 19) 34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
Multiply
spliced
11
12
5
4
10
22
18
97
100
85
64
62
210
23
140
44
3
1
238
23
1
3
45
9
4
23
45
29
UD
UD
0.4
UD
28
2
2
6
10
160
6
169
640
60
130
2
3
12
42
UD
25
UD
112
UD
Unspliced
UD
UD
UD
0.2
5
UD
3
UD
UD
UD
UD
UD
26
UD
6
7
11
0.4
2
0.8
UD
1
3
UD
0.5
0.6
25
UD
1
1
1
1.5
34
3
0.5
0.9
UD
20
1
18
280
5
15
3
0.8
1
7
30
8
44
114
1
i PBMCs from
R
Total
CD4-Lositive
cells, no./mm3
408
349
992
256
ND
ND
ND
ND
429
ND
ND
ND
405
ND
1050
ND
ND
339
612
572
39
5
21
ND
168
ND
84
584
28
ND
ND
ND
334
164
60
ND
80
6
37
ND
32
448
3
107
104
226
13
144
63
188
21
209
HIV-1-specific RNA is expressed as copies (x 10-6) per ,.&g of total
cellular RNA. UD, undetectable; ND, not determined. The lower
limit of detection sensitivity for this quantitative RT-PCR was 1 x 104
copies for both multiply spliced HIV-1 RNA and unspliced HIV-1
RNA. Two samples from each patient were tested, in duplicate, in at
least two experiments. Standard deviations between experiments
and samples, for both species of HIV-1 RNA in the PBMCs from
each individual evaluated, were always <1%o.
in the asymptomatic individuals is consistent with a high
fraction of blocked early-stage latently infected cells in the
peripheral blood of these individuals.
Table 2. Median levels of HIV-1-specific RNA species in
PBMCs from HIV-1-infected individuals
HIV-1-specific RNA Multiply
spliced/
Multiply unspliced
Stage spliced Unspliced HIV-1 RNA
2 (n = 20) 23 (1-238) 0.15 (<0.1-26) 85/1
3 (n = 13) 9 (<0.1-45) 1 (<0.1-34) 3/1
4 (n = 19) 10 (<0.1-640) 7 (<0.1-280) 5/1
Median level of HIV-i-specific RNA is expressed as copies (x
10-6) per ,ug of total cellular RNA. The range is in parentheses. The
individual ratios of multiply spliced to unspliced viral RNA levels, in
each clinical stage, underwent logarthmic transformation prior to
ranking the ratios for computation of the median ratio in each group.
A more informative way to view the data is to classify the
various HIV-1 RNA patterns and examine the distribution of
the classes as a function of the clinical stage of infection. In
previous work, this group (11, 13) and others (12) have
demonstrated that during acute productive HIV-1 infections,
in cell cultures, the patterns of HIV-1 RNA expression are
ones in which multiply spliced HIV-1 RNA levels and levels
of unspliced genomic HIV-1 RNA do not dramatically differ.
If we consider that any sample with a 10-fold excess of
multiply spliced RNA can be classified as a state of "pre-
dominantly blocked early-stage latency," then 70o of the
stage 2 individuals fit this definition (Table 3). By contrast,
38% of the stage 3 individuals and only 16% of the stage 4
patients display a pattern indicative of predominant latency.
Thus, most of these latter patients' PBMCs fit the criterion of
"'significant productive cells" [Table 3: the difference be-
tween stage 2 and stage 4 samples was highly statistically
significant (P < 0.001), by Fisher's exact test].
There were two extreme patterns of HIV-1 RNA, no
detectable unspliced RNA or solely unspliced RNA. Of the
stage 2 individuals, 50% had no unspliced HIV-1 RNA
detected whereas 23% of the stage 3 and only 5% of the stage
4 showed this pattern [Table 3: the difference between stage
2 and stage 4 samples was highly significant (P < 0.001)]. This
is presumably due to a vast excess of blocked early-stage
latently infected cells in asymptomatic patients. The opposite
pattern, only unspliced HIV-1 RNA, was found in no stage 2
individuals but in six stage 3 and stage 4 patients. It could be
indicative of a vast excess of productively infected cells in
these individuals, as multiply spliced HIV-1 RNA will grad-
ually decrease in a productive infection in cell cultures,
possibly secondary to feedback from the viral-encoded pro-
tein Rev (10). These data suggest that a viral RNA pattern
consistent with blocked early-stage latency is more com-
monly demonstrated in asymptomatic HIV-1-infected pa-
tients, as compared to patients with AIDS.
DISCUSSION
This study was undertaken to determine whether a specific
form of proviral latency, blocked early-stage latency, might
be a common state of HIV-1 in cells of individuals who are
in the asymptomatic phase of the infection. For the word
"latency" to be relevant does not require that there be no
viral expression, only that there be little virus production
relative to a full-blown productive state. A variety of animal
lentiviruses, to which HIV-1 is closely related, have been
demonstrated to maintain a state of proviral latency for
variable lengths of time (22).
Latency is a word often used in connection with HIV-1
infection (6); it implies that the viral genome is present but is
not extensively expressed. This could refer to the entire
infected individual, where some cells harbor the viral genome
but little virus is expressed in the circulation, or it could be
Medical Sciences: Sesharnma et al.
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Table 3. Patterns of HIV-1-specific RNA species
Individuals, no.
Blocked No multiply
Productive early-stage No unspliced spliced HIV-1
pattern of latent pattern HIV-1 RNA RNA
Stage HIV-1 RNA of HIV-1 RNA detected detected
2 (n = 20) 6 (30) 14 (70) 10 (50) 0 (0)
3 (n = 13) 8 (62) 5 (38) 3 (23) 3 (23)
4 (n = 19) 16 (84) 3 (16) 1(5) 3 (16)
Blocked early-stage latent HIV-1 RNA pattern was defined as a 10-fold or higher level of multiply
spliced HIV-1 RNA, as compared to unspliced HIV-1 RNA (see text). The number of individuals in
each HIV classification stage expressing a particular HIV-1 RNA pattern, in their PBMCs, is presented
in this table. The percentage of individuals in each stage expressing a particular HIV-1 RNA pattern,
in their PBMCs, is shown in parentheses. Ofnote, those individuals expressing no detectable unspliced
HIV-1 RNA and those expressing no detectable multiply spliced HIV-1 RNA are considered subgroups
ofthe latent and productive patterns ofHIV-1 RNA, respectively. Those samples in which no unspliced
HIV-1 RNA was detected, using the original primers, also demonstrated the same HIV-1 RNA
expression pattern using gag primers (21). These gag primers consistently detected unspliced HIV-1
RNA in those samples in which the original primers, for unspliced HIV-1 RNA, yielded positive results
(data not shown). Thus, by this test, heterogeneity of the HIV-1 genome did not appear to account for
those PBMC samples in which no unspliced HIV-1 RNA was detected.
in cells of the HIV-1-infected person, in which the viral
genome is present but there is little virus production. Latency
could come about through a variety of means. It could result
if the viral genomes were incompletely or completely repli-
cated and unintegrated but maintained until the infected cell
received an activation signal, as has been suggested for
infection of resting T lymphocytes (23, 24). While the RNA
patterns we found in patient samples are indicative ofblocked
early-stage latency, they could have other interpretations.
For instance, they could be due to defective viral genomes or
defective cells that are unable to progress to later stages of
infection. Thus, these viral RNA patterns may correlate with
various strains of HIV-1 isolates (25).
Our data agree with reports in which HIV-1 RNA could be
detected in the PBMCs of most individuals with HIV-1
infections (20, 21). It is evident that in the vast majority of
HIV-1-seropositive individuals, regardless of disease stage,
significant numbers of cells are transcribing HIV-1 RNA.
Nevertheless, our studies demonstrate significant differences
in the patterns of HIV-1-specific RNA, based on clinical
stage of disease. In a study utilizing a nonquantitative RT-
PCR technique, Gag-encoding HIV-1 RNA was less fre-
quently detected in PBMCs of patients with high CD4-
positive lymphocyte counts than in patients with low CD4-
positive lymphocyte counts (21).
It is important to fit these observations into a general
conception of the evolution of an HIV-1 infection in a newly
infected individual. A newly HIV-1-infected individual ex-
periences an initial productive infection, involving extensive
viral proliferation over numerous weeks (1, 2). Thereafter,
the immune system would seem to partially control the HIV-1
infection, reducing the circulating titer of virus and produc-
tively infected cells to very low levels (4, 5, 26). At this stage,
a preponderance of CD4-positive lymphocytes harboring
blocked early-stage latent infections would exist in the pe-
ripheral blood of asymptomatic HIV-1-infected individuals.
The final stage of infection probably comes about when
CD4-positive lymphocyte function has been so compromised
that the humoral and cellular immune control of the infection
fails, with an outgrowth of productively infected cells.
We derive from these data a picture of clinical HIV-1
infection characterized by at least two types of HIV-1-
infected cells. One type of cell is productively infected and is
rare in asymptomatic HIV-1-infected individuals and in pa-
tients with AIDS, and the second type of HIV-1-infected cell
is blocked in the early stage of infection. The productively
infected cells were detected using in situ hybridization and
were determined to be in 1 of 10,000 to 1 of 100,000 total
lymphocytes (27). Recent analyses have demonstrated that
the number of cells harboring HIV-1 proviruses is vastly in
excess of the number producing HIV-1 RNA detectable by
the in situ hybridization technique (4, 21, 28). Many of these
cells may be blocked early-stage latently infected cells.
Importantly, preliminary data suggest that latently infected
cells may be less common in lymphoid tissue than in PBMCs
(29).
The predominance of blocked early-stage latently infected
cells may have important clinical significance. The viral RNA
expression pattern of blocked early-stage latency in periph-
eral blood cells will be important to further correlate with
disease progression and, thus, may potentially be useful as a
surrogate marker to follow during the course of HIV-1
infection in patients (30). Additional long-range follow-up
studies ofHIV-1 RNA expression patterns in HIV-1-infected
patients are ongoing. Our data also suggest that HIV-1-
infected individuals have a reservoir of cells whose infected
state will be maintained even in the face of treatment with
anti-RT compounds. Such drugs can only prevent new in-
fections of cells; they cannot clear HIV-1 latently infected
cells.
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